Takeshi Iwatsubo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7736622/publications.pdf

Version: 2024-02-01

53660 17546 20,642 120 45 citations h-index papers

g-index 150 150 150 20945 docs citations times ranked citing authors all docs

121

#	Article	IF	CITATIONS
1	Stateâ€ofâ€theâ€art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177.	0.4	33
2	ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity. Neurobiology of Disease, 2022, 162, 105585.	2.1	19
3	Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. Journal of Psychiatric Research, 2022, 148, 159-164.	1.5	5
4	Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. European Neuropsychopharmacology, 2022, 57, 50-58.	0.3	2
5	Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer's disease. IScience, 2022, 25, 103869.	1.9	7
6	Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. Journal of Experimental Medicine, 2022, 219, .	4.2	93
7	Dissection of the polygenic architecture of neuronal AÎ ² production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. Nature Aging, 2022, 2, 125-139.	5.3	7
8	Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database. BioScience Trends, 2022, , .	1.1	1
9	Automated Evaluation of Conventional Clock-Drawing Test Using Deep Neural Network: Potential as a Mass Screening Tool to Detect Individuals With Cognitive Decline. Frontiers in Neurology, 2022, 13, 896403.	1.1	11
10	Long non-coding RNA NEAT1_1 ameliorates TDP-43 toxicity in in vivo models of TDP-43 proteinopathy. RNA Biology, 2021, 18, 1546-1554.	1.5	27
11	Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. European Psychiatry, 2021, 64, e16.	0.1	1
12	Tauroursodeoxycholic Acid Attenuates Diet-Induced and Age-Related Peripheral Endoplasmic Reticulum Stress and Cerebral Amyloid Pathology in a Mouse Model of Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-12.	1.5	6
13	The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan: Evaluation of an administrative claims database. BioScience Trends, 2021, 15, 219-230.	1.1	11
14	The Amyloid-β Pathway in Alzheimer's Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	4.1	478
15	Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. Journal of Alzheimer's Disease, 2021, 82, 1075-1084.	1.2	5
16	Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database. International Journal of Infectious Diseases, 2021, 111, 310-312.	1.5	48
17	Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2021, 159, 105510.	2.1	9
18	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trialâ€Ready Cohort study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12135.	1.8	11

#	Article	IF	CITATIONS
19	Alzheimer's Disease Research in Japan: A Short History, Current Status and Future Perspectives toward Prevention. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-3.	1.5	1
20	Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale–Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. Evidence-Based Mental Health, 2021, 24, 56-61.	2.2	14
21	Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study. Journal of Medical Internet Research, 2021, 23, e26284.	2.1	4
22	Experts' perception of support for people with dementia and their families during the COVID $\hat{a}\in \mathbb{R}^9$ pandemic. Geriatrics and Gerontology International, 2021, , .	0.7	3
23	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNIâ€3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12226.	1.8	23
24	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. International Journal of Molecular Sciences, 2021, 22, 13136.	1.8	20
25	Evaluation of PiB visual interpretation with CSF AÎ 2 and longitudinal SUVR in J-ADNI study. Annals of Nuclear Medicine, 2020, 34, 108-118.	1.2	7
26	Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation. Neurobiology of Disease, 2020, 145, 105081.	2.1	49
27	Attempt to Predict A/T/N-Based Alzheimer's Disease Cerebrospinal Fluid Biomarkers Using a Peripheral Blood DNA Methylation Clock. Journal of Alzheimer's Disease Reports, 2020, 4, 287-296.	1.2	6
28	Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid- \hat{l}^2 plaques. Acta Neuropathologica Communications, 2020, 8, 212.	2.4	13
29	Behavioral and electrophysiological evidence for a neuroprotective role of aquaporin-4 in the 5xFAD transgenic mice model. Acta Neuropathologica Communications, 2020, 8, 67.	2.4	27
30	Effect of apolipoprotein E $\hat{l}\mu4$ allele on the progression of cognitive decline in the early stage of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12007.	1.8	20
31	The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System. Frontiers in Neuroscience, 2020, 14, 227.	1.4	47
32	A Novel Method to Estimate Longâ€Term Chronological Changes From Fragmented Observations in Disease Progression. Clinical Pharmacology and Therapeutics, 2019, 105, 436-447.	2.3	12
33	Calcium-responsive transactivator (CREST) toxicity is rescued by loss of PBP1/ATXN2 function in a novel yeast proteinopathy model and in transgenic flies. PLoS Genetics, 2019, 15, e1008308.	1.5	5
34	Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysis. NeuroImage: Clinical, 2019, 24, 101957.	1.4	11
35	Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid \hat{l}^2 fibrils. PLoS ONE, 2019, 14, e0219465.	1.1	11
36	Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 364-373.	1.8	11

#	Article	IF	CITATIONS
37	Chronic cerebral hypoperfusion shifts the equilibrium of amyloid \hat{l}^2 oligomers to aggregation-prone species with higher molecular weight. Scientific Reports, 2019, 9, 2827.	1.6	27
38	Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 15.	4.4	74
39	Collagen XXV promotes myoblast fusion during myogenic differentiation and muscle formation. Scientific Reports, 2019, 9, 5878.	1.6	17
40	Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative. Journal of Alzheimer's Disease, 2019, 68, 777-788.	1.2	15
41	Roles of Collagen XXV and Its Putative Receptors PTP $\ f\ ^2$ in Intramuscular Motor Innervation and Congenital Cranial Dysinnervation Disorder. Cell Reports, 2019, 29, 4362-4376.e6.	2.9	16
42	Seeding Activity-Based Detection Uncovers the Different Release Mechanisms of Seed-Competent Tau Versus Inert Tau via Lysosomal Exocytosis. Frontiers in Neuroscience, 2019, 13, 1258.	1.4	14
43	VI. Lifestyle Diseases and Dementia: Update on Pathophysiology, Prevention, and Treatment. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 701-707.	0.0	0
44	Self-assembly of FUS through its low-complexity domain contributes to neurodegeneration. Human Molecular Genetics, 2018, 27, 1353-1365.	1.4	19
45	Loss of kallikreinâ€related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Molecular Medicine, 2018, 10, .	3.3	39
46	Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology. Biochemical and Biophysical Research Communications, 2018, 495, 1708-1715.	1.0	78
47	Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 645-651.	1.8	16
48	LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9115-E9124.	3.3	222
49	Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. Acta Neuropathologica, 2018, 136, 569-587.	3.9	47
50	Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer's Disease Neuroimaging Initiative study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 765-774.	1.8	20
51	Extracellular \hat{l} ±-synuclein levels are regulated by neuronal activity. Molecular Neurodegeneration, 2018, 13, 9.	4.4	100
52	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's and Dementia, 2018, 14, 1077-1087.	0.4	83
53	Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9645-E9654.	3.3	72
54	Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2017, 56, 75-88.	1.2	31

#	Article	IF	Citations
55	BIN1 regulates BACE1 intracellular trafficking and amyloid- \hat{l}^2 production. Human Molecular Genetics, 2016, 25, ddw146.	1.4	67
56	Partial loss of CALM function reduces A \hat{l}^2 42 production and amyloid deposition (i) in vivo (i). Human Molecular Genetics, 2016, 25, 3988-3997.	1.4	24
57	Familial Amyotrophic Lateral Sclerosis-linked Mutations in Profilin 1 Exacerbate TDP-43-induced Degeneration in the Retina of Drosophila melanogaster through an Increase in the Cytoplasmic Localization of TDP-43. Journal of Biological Chemistry, 2016, 291, 23464-23476.	1.6	17
58	LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Scientific Reports, 2016, 6, 29945.	1.6	111
59	A novel non-canonical Notch signaling regulates expression of synaptic vesicle proteins in excitatory neurons. Scientific Reports, 2016, 6, 23969.	1.6	13
60	Phantom criteria for qualification of brain FDG and amyloid PET across different cameras. EJNMMI Physics, 2016, 3, 23.	1.3	31
61	Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2015, 10, 20.	4.4	25
62	Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 36.	3.0	31
63	Synthetic ceramide analogues increase amyloid- \hat{l}^2 42 production by modulating \hat{l}^3 -secretase activity. Biochemical and Biophysical Research Communications, 2015, 457, 194-199.	1.0	24
64	Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain. Human Molecular Genetics, 2015, 24, 540-558.	1.4	70
65	Cooperative Roles of Hydrophilic Loop 1 and the C-Terminus of Presenilin 1 in the Substrate-Gating Mechanism of \hat{I}^3 -Secretase. Journal of Neuroscience, 2015, 35, 2646-2656.	1.7	48
66	Role of Apolipoprotein E in β-Amyloidogenesis. Journal of Biological Chemistry, 2015, 290, 15163-15174.	1.6	46
67	Chronic Optogenetic Activation Augments A \hat{l}^2 Pathology in a Mouse Model of Alzheimer Disease. Cell Reports, 2015, 11, 859-865.	2.9	186
68	Lack of Correlation between the Kinase Activity of LRRK2 Harboring Kinase-Modifying Mutations and Its Phosphorylation at Ser910, 935, and Ser955. PLoS ONE, 2014, 9, e97988.	1.1	27
69	CLAC-P/Collagen Type XXV Is Required for the Intramuscular Innervation of Motoneurons during Neuromuscular Development. Journal of Neuroscience, 2014, 34, 1370-1379.	1.7	41
70	Allosteric regulation of \hat{l}^3 -secretase activity by a phenylimidazole-type \hat{l}^3 -secretase modulator. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10544-10549.	3.3	72
71	Decreased CALM expression reduces \hat{Al}^2 42 to total \hat{Al}^2 ratio through clathrin-mediated endocytosis of \hat{l}^3 -secretase. Nature Communications, 2014, 5, 3386.	5.8	78
72	Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes. Structure, 2014, 22, 125-135.	1.6	56

#	Article	IF	CITATIONS
73	Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2014, 370, 311-321.	13.9	1,387
74	Imago Mundi, Imago AD, Imago ADNI. Alzheimer's Research and Therapy, 2014, 6, 62.	3.0	5
75	New photocleavable linker: α-Thioacetophenone-type linker. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2831-2833.	1.0	7
76	A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. New England Journal of Medicine, 2013, 369, 341-350.	13.9	1,005
77	Comparison between brain <scp>CT</scp> and <scp>MRI</scp> for voxelâ€based morphometry of <scp>A</scp> zheimer's disease. Brain and Behavior, 2013, 3, 487-493.	1.0	34
78	Differential Effects of Familial Parkinson Mutations in LRRK2 Revealed by a Systematic Analysis of Autophosphorylation. Biochemistry, 2013, 52, 6052-6062.	1.2	19
79	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
80	RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Human Molecular Genetics, 2013, 22, 4474-4484.	1.4	68
81	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 280-292.	0.4	5,550
82	Japanese Alzheimer's Disease Neuroimaging Initiative: Present status and future. Alzheimer's and Dementia, 2010, 6, 297-299.	0.4	81
83	Single Chain Variable Fragment against Nicastrin Inhibits the Î ³ -Secretase Activity. Journal of Biological Chemistry, 2009, 284, 27838-27847.	1.6	19
84	$\hat{Al^2}$ Immunotherapy: Intracerebral Sequestration of $\hat{Al^2}$ by an Anti- $\hat{Al^2}$ Monoclonal Antibody 266 with High Affinity to Soluble $\hat{Al^2}$. Journal of Neuroscience, 2009, 29, 11393-11398.	1.7	103
85	The Tottori (D7N) and English (H6R) Familial Alzheimer Disease Mutations Accelerate AÎ ² Fibril Formation without Increasing Protofibril Formation. Journal of Biological Chemistry, 2007, 282, 4916-4923.	1.6	96
86	GTP Binding Is Essential to the Protein Kinase Activity of LRRK2, a Causative Gene Product for Familial Parkinson's Diseaseâ€. Biochemistry, 2007, 46, 1380-1388.	1.2	246
87	THIS ARTICLE HAS BEEN RETRACTED: Pathological biochemistry of αâ€synucleinopathy. Neuropathology, 2007, 27, 474-478.	0.7	31
88	Tauopathy: An overview. Neuropathology, 2006, 26, 455-456.	0.7	2
89	Alzheimer disease research in Japan: public funding. Nature Medicine, 2006, 12, 778-779.	15.2	3
90	CLAC Binds to Amyloid \hat{l}^2 Peptides through the Positively Charged Amino Acid Cluster within the Collagenous Domain 1 and Inhibits Formation of Amyloid Fibrils. Journal of Biological Chemistry, 2005, 280, 8596-8605.	1.6	52

#	Article	IF	CITATIONS
91	Discussions on role of neprilysin and degradating system. Psychogeriatrics, 2004, 4, S13-S18.	0.6	O
92	Discussions on laminin as possible biomarkers for neurodegenerative dementia. Psychogeriatrics, 2004, 4, S39-S44.	0.6	0
93	Discussions on phosphorylated tau and other biochemical markers. Psychogeriatrics, 2004, 4, S45-S50.	0.6	0
94	Assembly and activation of the \hat{I}^3 -secretase complex: roles of presentlin cofactors. Molecular Psychiatry, 2004, 9, 8-10.	4.1	14
95	The \hat{l}^3 -secretase complex: machinery for intramembrane proteolysis. Current Opinion in Neurobiology, 2004, 14, 379-383.	2.0	169
96	Mostly Separate Distributions of CLAC- versus A \hat{l}^2 40- or Thioflavin S-Reactivities in Senile Plaques Reveal Two Distinct Subpopulations of \hat{l}^2 -Amyloid Deposits. American Journal of Pathology, 2004, 165, 273-281.	1.9	30
97	Aggregation of ?-synuclein in the pathogenesis of Parkinson?s disease. Journal of Neurology, 2003, 250, 1-1.	1.8	49
98	The role of presenilin cofactors in the \hat{I}^3 -secretase complex. Nature, 2003, 422, 438-441.	13.7	839
99	APP Processing and Synaptic Function. Neuron, 2003, 37, 925-937.	3.8	1,423
100	Dementia of Old People: Recent Advances in Epidemiology, Diagnosis, Treatment, Care, and Research 2. Molecular Pathogenesis of Alzheimer's Disease. Internal Medicine, 2003, 42, 312.	0.3	1
101	Molecular pathogenesis of Alzheimer's disease. Internal Medicine, 2003, 42, 312.	0.3	0
102	α-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology, 2002, 4, 160-164.	4.6	1,739
103	CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO Journal, 2002, 21, 1524-1534.	3.5	184
104	Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii peninsula of Japan: Clinical and neuropathological study and tau analysis. Annals of Neurology, 2001, 49, 501-511.	2.8	108
105	Co-localization of \hat{l}_{\pm} -synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathologica, 2001, 101, 285-293.	3.9	74
106	Variant Alzheimer Disease With Spastic paraparesis: Neuropathological phenotype. Journal of Neuropathology and Experimental Neurology, 2001, 60, 483-492.	0.9	78
107	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Annals of Neurology, 2000, 47, 422-429.	2.8	109
108	Pick's disease is associated with mutations in thetau gene. Annals of Neurology, 2000, 48, 859-867.	2.8	131

#	Article	IF	CITATIONS
109	A novel mutation at position $+12$ in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto)., 2000, 47, 422.		6
110	Pick's disease is associated with mutations in the tau gene. Annals of Neurology, 2000, 48, 859-867.	2.8	7
111	C Terminus of Presenilin Is Required for Overproduction of Amyloidogenic A $\hat{1}^2$ 42 through Stabilization and Endoproteolysis of Presenilin. Journal of Neuroscience, 1999, 19, 10627-10634.	1.7	104
112	Amyloid .BETA. Peptides and Presenilins in the Pathogenesis of Alzheimer's Disease Acta Histochemica Et Cytochemica, 1999, 32, 13-15.	0.8	5
113	Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death and Differentiation, 1998, 5, 832-837.	5.0	272
114	Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble ?-synuclein. Annals of Neurology, 1998, 44, 415-422.	2.8	633
115	Mutant Presenilin 2 Transgenic Mouse: Effect on an Ageâ€Dependent Increase of Amyloid βâ€Protein 42 in the Brain. Journal of Neurochemistry, 1998, 71, 313-322.	2.1	81
116	Alzheimer's AÎ 2 (1â 4 2) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nature Medicine, 1997, 3, 1021-1023.	15.2	462
117	Monoclonal antibodies to purified cortical lewy bodies recognize the mid-size neurofilament subunit. Annals of Neurology, 1997, 42, 595-603.	2.8	48
118	Amyloid ? protein (A?) deposition: A?42(43) precedes A?40 in down Syndrome. Annals of Neurology, 1995, 37, 294-299.	2.8	378
119	Visualization of AÎ ² 42(43) and AÎ ² 40 in senile plaques with end-specific AÎ ² monoclonals: Evidence that an initially deposited species is AÎ ² 42(43). Neuron, 1994, 13, 45-53.	3.8	1,673
120	Bunina bodies in neurons of the medullary reticular formation in amyotrophic lateral sclerosis. Acta Neuropathologica, 1993, 85, 471-4.	3.9	20